SEC Form 4 · accession 0001123292-17-001446
OSIRIS THERAPEUTICS, INC. · OSIR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alla Danilkovitch
Officer — Chief Scientific Officer
Period of report
Jul 19, 2017
Accepted (ET)
Sep 28, 2017 · 5:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001360886
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F1 | $6.80 | Jul 19, 2017 | A | 34,534 | A | Jul 19, 2018 | Jul 19, 2027 | Common Stock | 34,534 | 125,534 | D |
| Non-qualified Stock Option (right to buy)F1 | $6.80 | Jul 19, 2017 | A | 15,466 | A | Jul 19, 2018 | Jul 19, 2027 | Common Stock | 15,466 | 139,000 | D |
Explanation of responses
- F125% of the shares underlying this option shall vest on each of July 19, 2018, July 19, 2019, July 19, 2020 and July 19, 2021, subject to Reporting Person's continued service through the applicable vesting date.